Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Alan Shaw

Gjalt Huisman

Codexis, Inc.

AMPLY Discovery leverages evolution and machine learning to discover new drugs through technology that digitizes biological diversity using next-generation sequencing.

AMPLY Discovery

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Austin Che

Tom Knight

Jason Kelly

Barry Canton

Reshma Shetty

Ginkgo Bioworks Holdings, Inc.

Codexis is a biotechnology company that develops biocatalysts for the pharmaceutical and fine chemical industries. Codexis utilizes its CodeEvolver platform to engineer enzymes for various applications.

Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins.

Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.

Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.

Innovatus Capital Partners

Casdin Capital

Maxygen

Chevron Technology Ventures

Pequot Capital

EDBI

CMEA Capital

We see incredible potential for enzymatic synthesis to support RNAi therapeutics manufacturing. 

To learn more, check out the interview our COO Kevin Norrett did with Genetic Engineering & Biotechnology News following our groundbreaking #TIDESUSA presentation last month.

#proteinengineering #enzymeengineering #RNAi

Join our SVP of Research Stefan Lutz for a panel discussion on scaling RNA therapies and a presentation by Mathew Miller discussing the cost effectiveness of manufacturing siRNA duplexes with engineered dsRNA ligases at RNA Leaders next week.

Several Codexians will be on the ground in San Diego for the conference. Message us here to set up a meeting with our team or stop by Booth #9 for an impromptu chat.

Safe travels to everyone heading to San Diego ✈️ and we'll see you there!

#RNALeaders #enzymeengineering #proteinengineering #RNAitherapeutics

Stefan, Matt, Kevin Norrett, Britton Jimenez, Mark Hochstetler and Jean Shieh - have a great meeting!

Who is joining us in San Diego for #RNALeaders?

Meet up with our Codexis team on the ground or join us for one of our two presentations on enzymatic synthesis for RNAi therapeutics.

Hit the follow button for more info on our presence at RNA Leaders and our market-leading enzymatic synthesis capabilities.

#proteinengineering #enzymeengineering #RNAitherapeutics

We're excited to share that today we issued our initial ESG disclosures aligned with the Sustainability Accounting Standards Board.

You can read more in our press release: https://bit.ly/4dmXLAs

#sustainability #ESG #governance #RNAitherapeutics

Today we issued our Q2 2024 financial results and provided a business update. 

Click below to read our press release and listen to our investor call beginning at 4:30 pm ET.

Link: https://bit.ly/3LYGn8U 

#codexis #proteinengineering #enzymeenginering #rnaitherapeutics

We are excited to be attending and sponsoring the RNA Leaders Conference next month in San Diego!

We'll have an entire team on the ground ready to chat all about our enzymatic synthesis capabilities. 

Want to meet up? Stop by Booth #9 or message us here to make an appointment. 

#RNALeaders #Codexis #proteinengineering #enzymeengineering #rnaitherapeutics

Codexis is reporting Q2 2024 financial results and providing a business update on Thursday, August 8th! 

Read our press release for all the details: https://lnkd.in/ef9B2HZr

Following our groundbreaking #TIDESUSA presentation last month, Codexis Chief Operating Officer Kevin Norrett had a virtual sit down with Genetic Engineering & Biotechnology News to discuss RNAi therapeutics manufacturing.

The resulting feature article highlights the need and urgency for another option to supplement traditional chemical manufacturing practices, which will face challenges of scale as more RNAi therapeutics make their way through the development process...there are of 450 of them in clinical trials right now!

Click the link below for the full article discussing enzymatic synthesis for RNAi therapeutics.

Link: https://lnkd.in/ej2uGzFc

#proteinengineering #enzymeengineering #RNAitherapeutics #RNAi

Each quarter we host an activity that supports our Community corporate value.

Sometimes this about our internal community as Codexians and strengthening our corporate culture.

Other times, it's about supporting the local communities in which we work and live.

Last week, we were thrilled to assemble 250 backpacks for rising kindergarten to 2nd grade students in our local community with the help of Family Giving Tree.

The team at FGT set up a brilliant assembly line in our Boardroom and we had everything packed in about 90 minutes! We laughed, we bumped into each other, we smiled and then we said we wish we had more to do.

If you're looking for a teambuilding activity in the Bay Area, definitely give L. Margarita Galindo MNA at FGT a call.

Huge thanks to Vesna Mitchell, Michael Whitehorn and the Codexis Activities Committee for bringing this opportunity to us! 

#giveback #communityrelations #proteinengineering #enzymeengineering #rnai #RNAitherapeutics

It's the last day of #TIDESUSA!

The Codexis crew is ready to talk all things enzyme engineering, ligation and RNAi therapeutics. Stop by Booth #628 to say hi and learn more!

#proteinengineering #enzymeengineering #RNAi #RNAitherapeutics #ligase

Metric
Company Name	Codexis, Inc.	AMPLY Discovery	Ginkgo Bioworks Holdings, Inc.
Symbol	CDXS		DNA
MSH ID	COM:CODEXIS	COM:AMPLYDISCOVERY	COM:GINKGOBIOWORKS
Market	STOCKS	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	GB	US
Stage			Grant
Employee Count	174	7	1.22K
Website	codexis.com	amplydiscovery.com	ginkgobioworks.com
LinkedIn	codexis		ginkgo-bioworks
Founders

Metric
Market Cap	204.62M	725.64M
Enterprise Value
Monthly Web Traffic	3.96K	20.69K
Web Traffic Growth	1.51	-0.17
Valuation
Raised Capital	40M

Metric
Revenue	70.14M	251.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit	51.82M	142.64M
EBITDA	-44.88M	-600.68M
Operating Income	-54.80M	-672.23M
Net Income	-76.24M	-892.87M
EPS	-1.12	-0.46
Diluted EPS	-1.12	-0.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.81	0.75
Operating Profit Margin	-0.76	-3.34
EBITDA Margin	-0.64	-2.39
Net Profit Margin	-0.88	-3.55
Return on Equity	-0.68	-0.65
Return on Assets	-0.44	-0.54
Return on Capital Employed	3.80	-0.51

COM:CODEXIS

Codexis

Last Close

4.33

22/11 21:00

Market Cap

204.62M

Beta: -

Volume Today

700.76K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.27	-2.78
P/B Ratio	2.03	1.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.12	93.70
EV Multiple	-4.84	-1.34

Metric
Days Sales Outstanding	94.23	73.17
Days Payables Outstanding	61.44	50.57
Days Inventory Outstanding	69.87	0.27
Operating Cycle	173.57	46.33
Cash Conversion Cycle	45.90	-7.39
Asset Turnover	5.20	0.15

Metric
Operating Cash Flow	-52.64M	-295.50M
Free Cash Flow	-57.06M	-336.30M
Cash Flow to Debt	-1.19	-0.63
Operating Cash Flow/Sales	-0.69	-1.14
Free Cash Flow Yield	-0.12	-0.16

Metric
Cash & Equivalents	65.64M	948.86M
Accounts Receivable	20.25M	50.07M
Inventory	2.69M	46K
Goodwill	2.46M	49.24M
Debt to Capitalization	0.35	0.35
Debt to Assets	0.13	0.20
Current Ratio	2.68	6.78
Quick Ratio	3.63	5.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.11	0.94
R&D to Revenue	0.91	2.05
SG&A to Revenue		1.32